• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Inogen Inc (Amendment)

    2/14/24 4:00:17 PM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email
    SC 13G/A 1 fp0086869-9_sc13ga.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 13)*

     

    Inogen, Inc.

     

    (Name of Issuer)

     

    Common Stock, Par Value $0.001

     

    (Title of Class of Securities)

     

    45780L104

     

    (CUSIP Number)

     

    Eddie C. Brown

    Brown Capital Management, LLC

    1201 N. Calvert Street

    Baltimore, MD 21202

    (410) 837-3234

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    December 31, 2023

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [x] Rule 13d-1(b)

    [  ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 45780L104 13G Page 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Brown Capital Management, LLC

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) [  ]

    (b) [  ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Maryland

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.

    SOLE VOTING POWER

     

    527,055

    6.

    SHARED VOTING POWER

     

    None

    7.

    SOLE DISPOSITIVE POWER

     

    1,560,409

    8.

    SHARED DISPOSITIVE POWER

     

    None

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,560,409

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.69%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

     

     

     

    CUSIP No. 45780L104 13G Page 3 of 5 Pages

     

    Item 1. (a)

    Name of Issuer

    Inogen, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

    301 Coromar Drive

    Goleta, California 93117

     

    Item 2. (a)

    Name of Person Filing

    Brown Capital Management, LLC

         
      (b)

    Address of the Principal Office or, if none, residence

    1201 N. Calvert Street

    Baltimore, MD 21202

         
      (c)

    Citizenship

    Brown Capital Management, LLC is a Maryland Limited Liability Company

         
      (d)

    Title of Class of Securities

    Common Stock, Par Value $0.001

         
      (e)

    CUSIP Number

    45780L104

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [  ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [x] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

    CUSIP No. 45780L104 13G Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 1,560,409
    (b) Percent of class: 6.69%
    (c) Number of shares as to which the person has:  
      (i) Sole power to vote or to direct the vote: 527,055
      (ii) Shared power to vote or to direct the vote: None
      (iii) Sole power to dispose or to direct the disposition of: 1,560,409
      (iv) Shared power to dispose or to direct the disposition of: None

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    All of the shares of Common Stock set forth in Item 4 are owned by various investment advisory clients of Brown Capital Management, LLC, which is deemed to be a beneficial owner of those shares pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, due to its discretionary power to make investment decisions over such shares for its clients and/or its ability to vote such shares. In all cases, persons other than Brown Capital Management, LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of the shares. No individual client holds more than five percent of the class.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

     

    CUSIP No. 45780L104 13G Page 5 of 5 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Brown Capital Management, LLC  
           
      By: /s/ Eddie C. Brown  
      Name: Eddie C. Brown  
      Title: CEO  
           
      Date: February 14, 2024  

     

     

    Get the next $INGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    11/5/2021$72.00 → $42.00Market Perform
    SVB Leerink
    11/2/2021$71.00 → $45.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $INGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inogen Announces First Quarter 2025 Financial Results

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p

      5/7/25 4:05:00 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen to Report First Quarter 2025 Financial Results on May 7, 2025

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo

      4/16/25 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen To Present at 24th Annual Needham Virtual Healthcare Conference

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 24th Annual Needham Virtual Healthcare Conference. Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website,

      3/20/25 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Financials

    Live finance-specific insights

    See more
    • Inogen Announces First Quarter 2025 Financial Results

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p

      5/7/25 4:05:00 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen to Report First Quarter 2025 Financial Results on May 7, 2025

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo

      4/16/25 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen Announces Fourth Quarter and Full Year 2024 Financial Results

      Results Reflect Strong Fourth Quarter 2024 Revenue Growth of 5.5%; Full-Year Revenue Growth of 6.4% Company Provides 2025 Growth Outlook Recently Announced Strategic Collaboration with Yuwell to Expand Product Portfolio, Global Reach Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter and the full year ended December 31, 2024. "2024 was a stellar year for Inogen. With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, President and Ch

      2/25/25 4:05:00 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:42:36 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • CEO and President Smith Kevin Raymond Merrill was granted 55,475 shares, converted options into 28,333 shares, covered exercise/tax liability with 39,797 shares and bought $100,245 worth of shares (11,709 units at $8.56), increasing direct ownership by 383% to 70,274 units (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:41:11 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Ramade Gregoire

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:44:50 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • EVP, Bus Dev, GC & Sec Smith Kevin P. was granted 1,186 shares (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:43:26 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:42:36 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $INGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Inogen Inc

      SC 13G/A - Inogen Inc (0001294133) (Subject)

      11/14/24 11:12:09 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Inogen Inc

      SC 13G - Inogen Inc (0001294133) (Subject)

      4/23/24 8:25:34 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Inogen Inc (Amendment)

      SC 13G/A - Inogen Inc (0001294133) (Subject)

      2/14/24 4:00:17 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen upgraded by William Blair

      William Blair upgraded Inogen from Mkt Perform to Outperform

      2/15/24 6:28:38 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen downgraded by JP Morgan with a new price target

      JP Morgan downgraded Inogen from Overweight to Neutral and set a new price target of $8.00 from $15.00 previously

      8/8/23 6:37:35 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen downgraded by Needham

      Needham downgraded Inogen from Buy to Hold

      7/14/23 7:51:45 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Inogen Inc

      10-Q - Inogen Inc (0001294133) (Filer)

      5/8/25 4:12:28 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Inogen Inc (0001294133) (Filer)

      5/7/25 4:07:15 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Inogen Inc

      DEFA14A - Inogen Inc (0001294133) (Filer)

      3/27/25 8:03:28 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

      MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

      11/7/24 4:04:00 PM ET
      $INGN
      $SGHT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Inogen Appoints Eric Pauls as Vice President of Sales, North America

      Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Mr. Pauls joins Inogen from RQM+, where he served as Chief Customer Officer. Kevin Smith, President and Chief Executive Officer of Inogen said, "We are excited to welcome Eric to the Inogen team. With over 20 years of experience driving growth and leading high-performing teams in the respiratory care business, his leadership will be instrumental as we expand our product offerings and solutions for patients with respiratory conditions in the Uni

      9/5/24 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care